Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Bristol Myers Squibb (BMS) has secured another win for Opdivo (nivolumab), becoming the only FDA-approved PD-1 inhibitor for resectable non-small cell lung cancer NSCLC in both a neoadjuvant-only ...

Nano Dimension Ltd., together with its subsidiaries, provides industrial manufacturing solutions for design-to-manufacturing of electronics and mechanical parts in the Americas, the Asia Pacific, ...

Nano One Materials Corp. engages in the production and sale of cathode active materials for lithium-ion battery applications in electric vehicles, energy storage systems, and consumer electronics. The ...

Nanomedicine is a branch of medicine that applies the knowledge and tools of nanotechnology to the prevention and treatment of disease. Nanomedicine involves the use of nanoscale materials, such as ...